Philips Becomes Exclusive Distributor of Corindus Cath Lab Robotic System

CorPath 200 system is the world’s first robotic-assisted system for the minimally invasive treatment of obstructed coronary arteries

 

August 23, 2012

Philips Healthcare and Corindus Vascular Robotics announced in August 2012 a distribution agreement for Corindus’ CorPath 200 System. The system was recently cleared by the U.S. Food and Drug Administration (FDA) and is the world first robotic-assisted system for the minimally invasive as percutaneous coronary intervention (PCI) of obstructed coronary arteries.

The financial details of the exclusive distribution agreement were not disclosed. Philips owns a minority share in Corindus Vascular Robotics.

The CorPath 200 can be integrated with all major X-ray fluoroscopy systems, including Philips’ Allura X-ray equipment. The robotic-assisted system is a compact and cost-efficient system that can be used with standard stents, catheters and guidewires. The distribution agreement enables both companies to sell this unique robotic-assisted system in the United States, addressing an immediate need of patients, interventional cardiologists and staff. This agreement is the next step in the alliance between Philips and Corindus, which was announced in 2011.

The CorPath 200 system has been designed for the robotic-assisted placement of the coronary guidewires and stent/balloon catheters used in PCI procedures. It is operated by the interventional cardiologist from a radiation-shielded, interventional cockpit. Additionally, the seated position in front of monitors may provide enhanced measurement and view of the angiography screen, while reducing fatigue and head, neck and back strain.

For more information: www.philips.com/newscenter, www.corindus.com